Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer's disease.

  • Source: Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2023 Nov 17; Vol. 9 (4), pp. e12429. Date of Electronic Publication: 2023 Nov 17 (Print Publication: Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101650118 Publication Model:

Record details

×
Academic Journal

AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery.

  • Authors : Potjewyd FM; UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Structural Genomics Consortium Chapel Hill North Carolina USA.; Annor-Gyamfi JK

  • Source: Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2022 Apr 20; Vol. 8 (1), pp. e12246. Date of Electronic Publication: 2022 Apr 20 (Print Publication: Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101650118 Publication Model:

Record details

×
Academic Journal

Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology.

  • Authors : Potjewyd FM; UNC Eshelman School of Pharmacy Division of Chemical Biology and Medicinal Chemistry Structural Genomics Consortium Chapel Hill North Carolina USA.; Annor-Gyamfi JK

  • Source: Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2022 Apr 12; Vol. 8 (1), pp. e12253. Date of Electronic Publication: 2022 Apr 12 (Print Publication: Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101650118 Publication Model:

Record details

×
  • 1-3 of  3 results for ""Mason, Emily""